{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T03:26:01Z","timestamp":1775791561671,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1007\/s12325-016-0407-5","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T13:24:48Z","timestamp":1474637088000},"page":"1867-1884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["A Review of Daclatasvir Drug\u2013Drug Interactions"],"prefix":"10.1007","volume":"33","author":[{"given":"Tushar","family":"Garimella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reena","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Pang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Kandoussi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bifano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Bertz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Eley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"407_CR1","unstructured":"World Health Organization. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva, Switzerland. http:\/\/www.who.int\/hiv\/pub\/hepatitis\/hepatitis-c-guidelines\/en\/ . Accessed April 15, 2015."},{"key":"407_CR2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrgastro.2013.106","volume":"10","author":"JJ Kiser","year":"2013","unstructured":"Kiser JJ, Burton JR Jr, Everson GT. Drug\u2013drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10:596\u2013606.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"407_CR3","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","volume":"32","author":"F McPhee","year":"2015","unstructured":"McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther. 2015;32:637\u201349.","journal-title":"Adv Ther."},{"key":"407_CR4","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1001\/jama.2015.3860","volume":"313","author":"F Poordad","year":"2015","unstructured":"Poordad F, Sievert W, Mollison L, et al. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA. 2015;313:1728\u201335.","journal-title":"JAMA"},{"key":"407_CR5","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.2015.3868","volume":"313","author":"AJ Muir","year":"2015","unstructured":"Muir AJ, Poordad F, Lalezari J, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015;313:1736\u201344.","journal-title":"JAMA"},{"key":"407_CR6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","volume":"63","author":"F Poordad","year":"2016","unstructured":"Poordad F, Schiff ER, Vierling JM, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016;63:1493\u2013505.","journal-title":"Hepatology"},{"key":"407_CR7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","volume":"373","author":"DL Wyles","year":"2015","unstructured":"Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:714\u201325.","journal-title":"N Engl J Med"},{"key":"407_CR8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease:\u00a0a randomized phase III study (ALLY-3\u00a0+). Hepatology. 2016;63:1430\u201341.","journal-title":"Hepatology"},{"key":"407_CR9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"407_CR10","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/S0168-8278(14)61461-6","volume":"60","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson I, et al. All-oral dual therapy with daclatasvir and asunaprevir in patients with HCV genotype 1b infection: phase 3 study results. J Hepatol. 2014;60(Suppl 1):S524\u20135.","journal-title":"J Hepatol"},{"key":"407_CR11","unstructured":"Bristol-Myers Squibb. Daklinza (daclatasvir) prescribing information 2016."},{"key":"407_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40261-015-0279-5","volume":"35","author":"M Bifano","year":"2015","unstructured":"Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug\u2013drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. Clin Drug Investig. 2015;35:281\u20139.","journal-title":"Clin Drug Investig"},{"key":"407_CR13","first-page":"17","volume":"6","author":"M Bifano","year":"2013","unstructured":"Bifano M, Sevinsky H, Stonier M, Jiang H, Bertz RJ. Daclatasvir, an HCV NS5A replication complex inhibitor, has minimal effect on pharmacokinetics of midazolam, a sensitive probe for cytochrome P450 3A4. Rev Antivir Ther Infect Dis. 2013;6:17.","journal-title":"Rev Antivir Ther Infect Dis."},{"key":"407_CR14","unstructured":"Bertz R. Bristol-Myers Squibb HCV full development portfolio overview. Plenary presentation presented at the 14th International Workshop on Clinical Pharmacology, April 22\u201324, 2014, Amsterdam, The Netherlands."},{"key":"407_CR15","unstructured":"Garimella T, Adamczyk R, Stonier M, et al. Effect of steady-state daclatasvir plus asunaprevir on the single-dose pharmacokinetics of the P-glycoprotein substrate digoxin in healthy adult subjects. Presented at ID Week 2014, October 8\u201312, 2014; Philadelphia, USA."},{"key":"407_CR16","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40261-014-0219-9","volume":"34","author":"T Eley","year":"2014","unstructured":"Eley T, Sevinsky H, Huang SP, et al. The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Clin Drug Investig. 2014;34:661\u201371.","journal-title":"Clin Drug Investig"},{"key":"407_CR17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s40262-015-0299-6","volume":"54","author":"T Eley","year":"2015","unstructured":"Eley T, Garimella T, Li W, Bertz RJ. Asunaprevir: a review of preclinical and clinical pharmacokinetics and drug\u2013drug interactions. Clin Pharmacokinet. 2015;54:1205\u201322.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"407_CR18","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/S0168-8278(13)60453-5","volume":"58","author":"X Wang","year":"2013","unstructured":"Wang X, Li W, Huang S, et al. Evaluation of pharmacokinetic drug\u2013drug interaction (DDI) between BMS-791325, an NS5B non-nucleoside polymerase inhibitor, daclatasvir and asunaprevir in triple combination in HCV genotype 1-infected patients [Abstract]. J Hepatol. 2013;58(Suppl 1):S184.","journal-title":"J Hepatol"},{"key":"407_CR19","first-page":"16","volume":"6","author":"T Eley","year":"2013","unstructured":"Eley T, You X, Huang S, et al. Evaluation of drug interaction potential between daclatasvir and sofosbuvir. Rev Antivir Ther Infect Dis. 2013;6:16.","journal-title":"Rev Antivir Ther Infect Dis."},{"key":"407_CR20","unstructured":"Janssen Therapeutics. OLYSIO\u2122 (simeprevir) Summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002777\/WC500167867.pdf . Accessed June 2016."},{"key":"407_CR21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","volume":"16","author":"L Platt","year":"2016","unstructured":"Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016;16:797\u2013808.","journal-title":"Lancet Infect Dis"},{"key":"407_CR22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11908-011-0229-1","volume":"14","author":"A Tseng","year":"2012","unstructured":"Tseng A, Foisy M. Important drug\u2013drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep. 2012;14:67\u201382.","journal-title":"Curr Infect Dis Rep."},{"key":"407_CR23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3851\/IMP2674","volume":"18","author":"M Bifano","year":"2013","unstructured":"Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931\u201340.","journal-title":"Antivir Ther."},{"key":"407_CR24","unstructured":"Gandhi Y, Adamczyk R, Wang R, et al. Assessment of drug\u2013drug interactions between daclatasvir and darunavir\/ritonavir or lopinavir\/ritonavir. Presented at the 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy 015, May 26\u201328, 2015, Washington DC, USA."},{"key":"407_CR25","doi-asserted-by":"crossref","first-page":"7903","DOI":"10.1128\/AAC.01603-15","volume":"59","author":"A Barrail-Tran","year":"2015","unstructured":"Barrail-Tran A, Vincent C, Furlan V, et al. Raltegravir pharmacokinetics in patients on asunaprevir-daclatasvir. Antimicrob Agents Chemother. 2015;59:7903\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR26","unstructured":"Song I, Jerva F, Zong J, et al. Evaluation of drug interactions between dolutegravir and daclatasvir in healthy subjects. Abstract 79 presented at the 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 26\u201328, 2015, Washington, DC."},{"key":"407_CR27","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(11)61097-0","volume":"378","author":"PK Nelson","year":"2011","unstructured":"Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378:571\u201383.","journal-title":"Lancet"},{"key":"407_CR28","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00478-15","volume":"59","author":"T Garimella","year":"2015","unstructured":"Garimella T, Wang R, Luo WL, et al. Assessment of drug\u2013drug interactions between daclatasvir and methadone or buprenorphine-naloxone. Antimicrob Agents Chemother. 2015;59:5503\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"407_CR29","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00004836-200603000-00009","volume":"40","author":"S Zacks","year":"2006","unstructured":"Zacks S, Beavers K, Theodore D, et al. Social stigmatization and hepatitis C virus infection. J Clin Gastroenterol. 2006;40:220\u20134.","journal-title":"J Clin Gastroenterol"},{"key":"407_CR30","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/PCC.v07n0503","volume":"7","author":"OC Gleason","year":"2005","unstructured":"Gleason OC, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005;7:225\u201330.","journal-title":"Prim Care Companion J Clin Psychiatry."},{"key":"407_CR31","unstructured":"Genentech USA I. COPEGUS\u2122 (ribavirin) package insert. 2013."},{"key":"407_CR32","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3851\/IMP2718","volume":"19","author":"M Bifano","year":"2014","unstructured":"Bifano M, Sevinsky H, Hwang C, et al. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate. Antivir Ther. 2014;19:511\u20139.","journal-title":"Antivir Ther."},{"key":"407_CR33","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. 2016. http:\/\/www.hcvguidelines.org . Accessed Sept 5, 2016."},{"key":"407_CR34","unstructured":"Gilead Sciences Inc. Sovaldi (sofosbuvir) US prescribing information. 2015."},{"key":"407_CR35","unstructured":"Bifano M, Connolly S, Hwang C, et al. The effect of co-administration of the proton-pump inhibitor omeprazole on the pharmacokinetics of daclatasvir in healthy subjects. Presented at the 48th Annual Meeting of the European Association for the Study of the Liver, April 24\u201328, 2013, Amsterdam, The Netherlands."},{"key":"407_CR36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1055\/s-0031-1298331","volume":"78","author":"BJ Gurley","year":"2012","unstructured":"Gurley BJ, Fifer EK, Gardner Z. Pharmacokinetic herb\u2013drug interactions (part 2): drug interactions involving popular botanical dietary supplements and their clinical relevance. Planta Med. 2012;78:1490\u2013514.","journal-title":"Planta Med"},{"key":"407_CR37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1067\/mcp.2001.113185","volume":"69","author":"S Malhotra","year":"2001","unstructured":"Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther. 2001;69:14\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"407_CR38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0167-4889(02)00345-2","volume":"1593","author":"H Matsuda","year":"2002","unstructured":"Matsuda H, Kinoshita K, Sumida A, et al. Taurine modulates induction of cytochrome P450 3A4 mRNA by rifampicin in the HepG2 cell line. Biochim Biophys Acta. 2002;1593:93\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"407_CR39","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C, Maasoumy B, Marra F, et al. Drug\u2013drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561\u20137.","journal-title":"Clin Infect Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T23:22:55Z","timestamp":1568416975000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0407-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,23]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["407"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0407-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,23]]}}}